Pipeline

We are building a pipeline of colon-targeted oral biologics to address serious gastrointestinal diseases where existing treatments are limited by systemic toxicity, poor patient adherence, and ineffective local delivery.

Our Focus Areas

We are currently developing programs in:

• Inflammatory Bowel Diseases (IBD)
  Including Crohn’s Disease and Ulcerative Colitis, where biologics have transformed care but still rely on injectable, systemic delivery — often leading to dose-limiting side effects and disease recurrence.

• Microsatellite Instability-High (MSI-H) Colorectal Cancer
  An immunotherapy-responsive subtype where local modulation of the tumor microenvironment could enhance outcomes in early-stage, neoadjuvant, or post-surgical settings — improving efficacy, reducing systemic toxicity, and enabling new combination strategies.

Despite billions invested in biologics, the GI tract remains underserved. Injected therapies often miss the target and cause off-site immune activation. Oral delivery platforms have struggled to protect and deliver complex molecules like monoclonal antibodies through the gut.

Our platform is designed to overcome these limitations — delivering functional biologics directly to the site of disease, while sparing the rest of the body.

Flexible by Design

Our technology is compatible with a wide range of biologic modalities — including monoclonal antibodies, cytokines, and enzymes — and can be applied to both existing biologics and early-stage candidates. This flexibility allows us to rapidly explore new indications, support partnered development, and expand into combination therapy strategies.